

# Infarto agudo de miocardio<sup>1</sup>

## Base de Datos Medline. Búsqueda hasta Septiembre 2004, artículos de revisión (review papers).

1. Quinn T. Managing acute myocardial infarction. *Emerg Nurse* 2004; 12(3):17-9.
2. Ott I. Tissue factor in acute coronary syndromes. *Semin Vasc Med* 2003;3(2):185-92.
3. Haas S. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes. *Semin Vasc Med* 2003;3(2):139-46.
4. Hackam DG, Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease. *Semin Vasc Med* 2003;3(3):323-32.
5. Kinlay S, Ganz P. Early statin therapy in acute coronary syndromes. *Semin Vasc Med* 2003;3(4):419-24.
6. Paoletti R, Gotto AM Jr, Hajjar DP. Inflammation in atherosclerosis and implications for therapy. *Circulation* 2004;109(23 Suppl 1):III20-6.
7. Wehrens XH, Doevendans PA. Cardiac rupture complicating myocardial infarction. *Int J Cardiol* 2004;95(2-3):285-92.
8. Pavlides GS, Cokkinos DV. Reperfusion therapy for acute myocardial infarction: drugs or devices? Is this the right question? *Clin Cardiol* 2004;27(5):254-6.
9. Saucedo JF, Henneby TA. Use of the early invasive approach in the management of acute coronary syndromes. *Curr Cardiol Rep*. 2004 Jul;6(4):287-91.
10. Adams J. Markers to define ischemia: are they ready for prime time use in patients with acute coronary syndromes? *Curr Cardiol Rep* 2004;6(4):253-8.
11. Bennett SK, Redberg RF. Acute coronary syndromes in women: is treatment different? Should it be? *Curr Cardiol Rep* 2004;6(4):243-52.
12. Nolan PE Jr. Integrating traditional and emerging treatment options in heart failure. *Am J Health Syst Pharm* 2004;61 Suppl 2:S14-22.
13. Fox KA. Management of acute coronary syndromes: an update. *Heart* 2004;90(6):698-706.
14. von Harsdorf R, Poole-Wilson PA, Dietz R. Regenerative capacity of the myocardium: implications for treatment of heart failure. *Lancet* 2004;363(9417):1306-13.
15. Schellinger PD, Kaste M, Hacke W. An update on thrombolytic therapy for acute stroke. *Curr Opin Neurol* 2004;17(1):69-77.
16. Wever EF, Robles de Medina EO. Sudden death in patients without structural heart disease. *J Am Coll Cardiol* 2004;43(7):1137-44.
17. Alam SE, Nasser SS, Fernainy KE, Habib AA, Badr KF. Cytokine imbalance in acute coronary syndrome. *Curr Opin Pharmacol* 2004;4(2):166-70.
18. Moukarbel GV, Ayoub CM, Abchee AB. Pharmacological therapy for myocardial reperfusion injury. *Curr Opin Pharmacol* 2004;4(2):147-53.
19. Fichtlscherer S, Heeschen C, Zeiher AM. Inflammatory markers and coronary artery disease. *Curr Opin Pharmacol* 2004;4(2):124-31.
20. Personen E, Liuba P. Footprints of atherosclerotic coronary heart disease in children. *Rev Port Cardiol* 2004;23(1):127-31.
21. Alhadi HA, Fox KA. Do we need additional markers of myocyte necrosis: the potential value of heart fatty-acid-binding protein. *QJM* 2004;97(4):187-98.
22. Danchin N. Acute coronary syndromes: should women receive less antithrombotic medication than men? *Heart* 2004;90(4):363-6.
23. Klein L, Gheorghiade M. Management of the patient with diabetes mellitus and myocardial infarction: clinical trials update. *Am J Med* 2004;116 Suppl 5A:47S-63S.
24. Masud SP, Mackenzie R. Acute coronary syndrome. *J R Army Med Corps* 2003;149(4):303-10.
25. Wernly JA. Ischemia, reperfusion, and the role of surgery in the treatment of cardiogenic shock secondary to acute myocardial infarction: an interpretative review. *J Surg Res* 2004;117(1):6-21.

<sup>1</sup> En colaboración con la Biblioteca Médica Nacional, UNAH (<http://cidbimena.desastres.hn>), y el Comité Consultivo de la Biblioteca Virtual en Salud de Honduras (<http://www.bvs.hn>).

26. Danchin N, De Benedetti E, Urban P. Acute myocardial infarction. *Clin Evid* 2003 J;(9):22-49.
27. Cheitlin MD. Should the patient with coronary artery disease use sildenafil? *Prev Cardiol* 2003;6(3):161-5.
28. Gawaz M, Muller I, Besta F. Combined antithrombotic therapy for acute coronary syndrome. *Semin Vasc Med* 2003;3(2):163-76.
29. Amrani DL, Port S. Cardiovascular disease: potential impact of stem cell therapy. *Expert Rev Cardiovasc Ther* 2003;1(3):453-61.
30. Reinhart WH. Fibrinogen--marker or mediator of vascular disease? *Vasc Med* 2003;8(3):211-6.
31. Cannon CP. The next step in cardiovascular protection. *Atheroscler Suppl* 2003;4(5):3-9.
32. Packer M. Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial. *J Card Fail* 2003;9(6):429-43.
33. Bartorelli AL. Hyperoxemic perfusion for treatment of reperfusion microvascular ischemia in patients with myocardial infarction. *Am J Cardiovasc Drugs* 2003;3(4):253-63.
34. de Zwaan C, van Dieijen-Visser MP, Hermens WT. Prevention of cardiac cell injury during acute myocardial infarction: possible role for complement inhibition. *Am J Cardiovasc Drugs* 2003;3(4):245-51.
35. Joseph AM, Fu SS. Smoking cessation for patients with cardiovascular disease: what is the best approach? *Am J Cardiovasc Drugs* 2003;3(5):339-49.
36. Timmermans F, De Sutter J, Gillebert TC. Stem cells for the heart, are we there yet? *Cardiology* 2003;100(4):176-85.
37. Weston C, Rao U. Antiplatelet drugs in cardiovascular diseases. *Int J Clin Pract* 2003;57(10):898-905.
38. Conforto A, Nuno I. Acute myocardial infarction: disposition to the operating room? *Emerg Med Clin North Am* 2003;21(4):779-802.
39. Milicevic Z, Raz I. Interventions in diabetic patients after myocardial infarction. *Acta Diabetol* 2003;40 Suppl 2:S348-53.
40. Szekendi MK; American College of Cardiology; American Heart Association. Compliance with acute MI guidelines lowers inpatient mortality. *J Cardiovasc Nurs* 2003;18(5):356-9.
41. Frye RL. Optimal care of patients with type 2 diabetes mellitus and coronary artery disease. *Am J Med* 2003;115 Suppl 8A:93S-98S.
42. Valgimigli M, Merli E, Malagutti P, Soukhomovskaia O, Cicchitelli G, Macri G, Ferrari R. Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress. *Arch Biochem Biophys* 2003;420(2):255-61.
43. Sunkomat JN, Gaballa MA. Stem cell therapy in ischemic heart disease. *Cardiovasc Drug Rev* 2003;21(4):327-42.
44. Aronow WS. Thrombolytic therapy is indicated for patients over 75 years of age with st-elevation acute myocardial infarction: antagonist viewpoint. *Am J Geriatr Cardiol* 2003;12(6):348-50.
45. Murray-Thomas T, Cowie MR. Epidemiology and clinical aspects of congestive heart failure. *J Renin Angiotensin Aldosterone Syst* 2003;4(3):131-6.
46. Raggi P. Role of coronary calcium screening in preventive cardiology. *Prev Cardiol* 2003;6(4):214-7.
47. Kereiakes DJ. Adjunctive pharmacotherapy before percutaneous coronary intervention in non-ST-elevation acute coronary syndromes: the role of modulating inflammation. *Circulation* 2003;108(16 Suppl 1):III22-7.
48. Topol EJ. Current status and future prospects for acute myocardial infarction therapy. *Circulation* 2003;108(16 Suppl 1):III6-13.
49. Califf RM. Supplement on acute coronary syndromes: introduction. *Circulation* 2003;108(16 Suppl 1):III1-5.
50. Murphy J. Pharmacological treatment of acute ischemic stroke. *Crit Care Nurs Q* 2003;26(4):276-82.
51. Tendera M, Wojakowski W. Role of antiplatelet drugs in the prevention of cardiovascular events. *Thromb Res* 2003;110(5-6):355-9.
52. Andreotti F, Conti E, Lanza GA, Crea F. Sex, survival bias, and mortality following acute myocardial infarction. *Ital Heart J* 2003;4(8):508-10.
53. Roe MT, Ohman EM, Pollack CV Jr, Peterson ED, Brindis RG, Harrington RA, Christenson RH, Smith SC Jr, Califf RM, Gibler WB. Changing the model of care for patients with acute coronary syndromes. *Am Heart J* 2003;146(4):605-12.
54. Cannon CP. Critical pathways for acute myocardial

- infarction. *Rev Cardiovasc Med* 2003;4 Suppl 3:S47-53.
55. Fonarow GC. The role of in-hospital initiation of cardiovascular protective therapies to improve treatment rates and clinical outcomes. *Rev Cardiovasc Med* 2003;4 Suppl 3:S37-46.
  56. Ito T, Ikeda U. Inflammatory cytokines and cardiovascular disease. *Curr Drug Targets Inflamm Allergy* 2003;2(3):257-65.
  57. Khan IA, Gowda RM. Clinical perspectives and therapeutics of thrombolysis. *Int J Cardiol* 2003;91(2-3):115-27.
  58. Kinlay S. Early statin therapy in acute coronary syndromes. *Minerva Cardioangiol* 2003;51(5):577-84.
  59. Gillespie M, Melby V. Assessing acute myocardial infarction. *Emerg Nurse* 2003;11(5):26-9.
  60. Lee KW, Lip GY. Acute coronary syndromes: Virchow's triad revisited. *Blood Coagul Fibrinolysis* 2003;14(7):605-25.
  61. Verjans JW, Narula N, Loyd A, Narula J, Vannan MA. Myocardial contrast echocardiography in acute myocardial infarction. *Curr Opin Cardiol* 2003;18(5):346-50.
  62. Apstein CS. The benefits of glucose-insulin-potassium for acute myocardial infarction (and some concerns). *J Am Coll Cardiol* 2003;42(5):792-5.
  63. Fernandez JS, Sadaniantz BT, Sadaniantz A. Review of antithrombotic agents used for acute coronary syndromes in renal patients. *Am J Kidney Dis* 2003;42(3):446-55.
  64. Herkner H, Thoennissen J, Nikfardjam M, Koreny M, Laggner AN, Mullner M. Short versus prolonged bed rest after uncomplicated acute myocardial infarction: a systematic review and meta-analysis. *J Clin Epidemiol* 2003;56(8):775-81.
  65. Holmes DR Jr. Cardiogenic shock: a lethal complication of acute myocardial infarction. *Rev Cardiovasc Med* 2003;4(3):131-5.
  66. Metz L, Waters DD. Implications of cigarette smoking for the management of patients with acute coronary syndromes. *Prog Cardiovasc Dis* 2003;46(1):1-9.
  67. Cucherat M, Bonnefoy E, Tremeau G. Primary angioplasty versus intravenous thrombolysis for acute myocardial infarction. *Cochrane Database Syst Rev* 2003;(3):CD001560.
  68. Spodick DH. Acute cardiac tamponade. *N Engl J Med*. 2003 Aug 14;349(7):684-90.
  69. Nappi J. Anemia in patients with coronary artery disease. *Am J Health Syst Pharm* 2003;60(14 Suppl 3):S4-8.
  70. Pfisterer M. Right ventricular involvement in myocardial infarction and cardiogenic shock. *Lancet* 2003;362(9381):392-4.
  71. Keating GM, Jarvis B. Carvedilol: a review of its use in chronic heart failure. *Drugs* 2003;63(16):1697-741.
  72. Carney RM, Freedland KE. Depression, mortality, and medical morbidity in patients with coronary heart disease. *Biol Psychiatry* 2003;54(3):241-7.
  73. Cannon CP. Elderly patients with acute coronary syndromes: higher risk and greater benefit from antiplatelet therapy and/or interventional therapies. *Am J Geriatr Cardiol* 2003;12(4):259-62.
  74. Berger AK. Thrombolysis in elderly patients with acute myocardial infarction. *Am J Geriatr Cardiol* 2003;12(4):251-6; quiz 257.

#### SITIOS WEB

1. <http://www.cdc.gov/nccdphp/cataloni.pdf>
2. [http://www.who.int/tobacco/research/heart\\_disease/en/](http://www.who.int/tobacco/research/heart_disease/en/)
3. [http://www.who.int/cardiovascular\\_diseases/prevention\\_control/en/](http://www.who.int/cardiovascular_diseases/prevention_control/en/)

#### REVISTA MEDICA HONDUREÑA

1. Bustamante Durón D, Almendarez Meza C. Perfil clínico epidemiológico en pacientes con Infarto Agudo del Miocardio. *Rev Med Hondur* 2000; 68: 9-14.

#### REVISTA MEDICA DE POSTGRADO UNAH

1. Moreno YY, Varela Ramos M. Análisis de la Evolución ambulatoria del paciente Post Infarto Agudo del Miocardio ingresados de los hospitales estatales y privados de Tegucigalpa. *Rev Med Post UNAH* 2000; 5: 165-169.
2. Chavarría Fajardo G, Turcios M. Uso del Magnesio en el infarto agudo de Miocardio. *Rev Med. Post UNAH* 2000; 5: 105-113.

**TESIS PARA OPTAR AL GRADO DE DOCTOR  
EN MEDICINA**

1. Gonzales Romero CH. Infarto agudo del miocardio: revisión estadística comparativa entre el Hospital Escuela y el IHSS durante un periodo de seis años consecutivos de enero de 1980 a junio de 1986. 616.1237 G64. 1986.
2. Muñoz Lara F. Infarto agudo en el miocardio: revisión estadística en el Hospital Escuela, durante el periodo comprendido de enero de 1979 al 30 de mayo de 1984. 616.124 M96. 1984.
3. Aguirre Mejía EL. Infarto agudo del Miocardio en el Hospital Escuela: Mortalidad y algunos factores que la condicionaron. 616.124 A28. 1990.



ESTOS SON LOS PRECEPTOS DEL DERECHO:

VIVIR HONESTAMENTE, NO OFENDER A LOS DEMÁS

Y DAR A CADA UNO LO SUYO.

*ULPIANO*